NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions.
about
The structure of NS-398 bound to cyclooxygenase-2COX-2/VEGF-dependent facilitation of tumor-associated angiogenesis and tumor growth in vivoClassic NSAID and selective cyclooxygenase (COX)-1 and COX-2 inhibitors in healing of chronic gastric ulcersSelective cyclo-oxygenase-2 inhibitors aggravate ischaemia-reperfusion injury in the rat stomachEffects of specific inhibition of cyclo-oxygenase-1 and cyclo-oxygenase-2 in the rat stomach with normal mucosa and after acid challengeDual inhibition of nitric oxide and prostaglandin production contributes to the antiinflammatory properties of nitric oxide synthase inhibitorsDiverse methyl sulfone-containing benzo[b]thiophene library via iodocyclization and palladium-catalyzed coupling.Substrate-selective COX-2 inhibition as a novel strategy for therapeutic endocannabinoid augmentationIdentification of a novel class of anti-inflammatory compounds with anti-tumor activity in colorectal and lung cancers.Up-regulation of COX-2 by inhibition of COX-1 in the rat: a key to NSAID-induced gastric injury.Role of thromboxane derived from COX-1 and -2 in hepatic microcirculatory dysfunction during endotoxemia in mice.Lipopolysaccharide-induced expression of microsomal prostaglandin E synthase-1 mediates late-phase PGE2 production in bone marrow derived macrophages.Pharmacokinetics and metabolism of orally administered firocoxib, a novel second generation coxib, in horses.Preclinical pharmacology of robenacoxib: a novel selective inhibitor of cyclooxygenase-2.Effects of selective inhibitors of cyclo-oxygenase-1 (COX-1) and cyclo-oxygenase-2 (COX-2) on the spontaneous myogenic contractions in the upper urinary tract of the guinea-pig and rat.Selective cyclooxygenase-2 inhibition: a target in cancer prevention and treatment.Differential effect of FR122047, a selective cyclo-oxygenase-1 inhibitor, in rat chronic models of arthritisPreclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2.Dual, but not selective, COX-1 and COX-2 inhibitors, attenuate acetic acid-evoked bladder irritation in the anaesthetised female cat.Intraplantar-injected ceramide in rats induces hyperalgesia through an NF-κB- and p38 kinase-dependent cyclooxygenase 2/prostaglandin E2 pathway.Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic.Recruitment of a prostaglandin E receptor subtype, EP3-expressing bone marrow cells is crucial in wound-induced angiogenesis.Effects of the novel anti-inflammatory compounds, N-[2-(cyclohexyloxy)-4-nitrophenyl] methanesulphonamide (NS-398) and 5-methanesulphonamido-6-(2,4-difluorothio-phenyl)-1-inda none (L-745,337), on the cyclo-oxygenase activity of human blood prostaglCerebrovascular cyclooxygenase-1 expression, regulation, and role in hypothalamic-pituitary-adrenal axis activation by inflammatory stimuli.Pathogenesis of NSAID-induced gastric damage: importance of cyclooxygenase inhibition and gastric hypermotilityThe coxib NSAIDs: potential clinical and pharmacologic importance in veterinary medicine.Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia, and interleukin 6 production in vivo.Cyclooxygenase-2 and its regulation in inflammation.LPS and TNF alpha modulate AMPA/NMDA receptor subunit expression and induce PGE2 and glutamate release in preterm fetal ovine mixed glial cultures.Aspirin Intolerance: Experimental Models for Bed-to-Bench.mPGES-1 as a target for cancer suppression: A comprehensive invited review "Phospholipase A2 and lipid mediators".Novel effects of the cyclooxygenase-2-selective inhibitor NS-398 on IL-1β-induced cyclooxygenase-2 and IL-8 expression in human ovarian granulosa cells.Combination treatment using the COX-2 inhibitor meloxicam and an anti-allergic in pollinosis.The nonsteroidal anti-inflammatory drug NS398 reactivates SPARC expression via promoter demethylation to attenuate invasiveness of lung cancer cells.Cytokine regulation of eicosanoid generation.Attenuated fever in pregnant rats is associated with blunted syntheses of brain cyclooxygenase-2 and PGE2.Pyrogenic cytokines injected into the rat cerebral ventricle induce cyclooxygenase-2 in brain endothelial cells and also upregulate their receptors.Both cyclooxygenase-1 and cyclooxygenase-2 mediate osteoblast response to titanium surface roughness.Functional coupling between various phospholipase A2s and cyclooxygenases in immediate and delayed prostanoid biosynthetic pathways.Prostaglandin E2 amplifies cytosolic phospholipase A2- and cyclooxygenase-2-dependent delayed prostaglandin E2 generation in mouse osteoblastic cells. Enhancement by secretory phospholipase A2.
P2860
Q27671771-60398E11-2AF5-4C29-9AC3-C07F40494B75Q28165693-3B1DE8B7-B1E4-4AC2-AC6B-89C66976F1FEQ28184249-6692E292-0C91-42A0-BCFD-24B78F4B2D8DQ28343775-75E7810D-3593-49E4-8DE7-F54C1170BE71Q28361239-0662A3A7-D4F2-4100-9D6A-2066D5F27B0EQ28367719-602544CF-2734-40F8-B1FF-DAFB348298DCQ33522431-9153B305-646F-4CA9-BF15-148A6D259EBAQ33819279-ADEDBB61-EBFF-4A02-9849-FC5BE97B5A84Q34024178-435208B7-6715-4F01-8E24-B7DB6BF61EFFQ34124785-FAC70DA9-BD2A-4DAA-9FAC-3823E9F3B722Q34293806-EE8E907E-C5A3-40EB-AAC0-E958D63F83F3Q34505205-FAA5B472-2B0F-4DFA-BE21-2DA72C3C2FBAQ34579145-4DE160D2-0659-4F29-B409-85E8E14B9680Q34603488-207157FA-6500-4CC5-928C-EB8B00A3B2A2Q35041946-37F6F00F-45FA-4EB2-A8A3-EAB7879C866AQ35043366-DEA19E2B-032E-4B12-9886-4979BB12C3F8Q35044089-74FC46AA-E92D-439F-AB6B-3F03C47F9E2AQ35048654-4DA56BF9-75EB-4BEE-99DC-BC7C3A29E325Q35100868-D28C26F0-A504-4ADB-B676-F04FB9BA92DCQ35105360-462F2938-AA32-4F33-A694-C7C1616AAA9DQ35163045-5F3FCD4B-BF16-43E9-B47A-AA7DE0F7F76FQ35607267-2664AC77-7AC2-41E2-A860-BEB55F47FB42Q35872952-D7B854F1-06E9-4E70-807A-4875D03E9FC7Q35886515-4FAE0AF9-8B76-428A-8BF4-03044A745C04Q35958226-FE52040D-E892-4D09-B5F0-E72788E7E0E1Q36289284-54823987-78F2-43C9-B0A2-F13B0B5B6A09Q36367310-5165CC36-FA57-464E-AADC-ACF0B91172DAQ36628126-65CFDEAA-1700-4DFE-B173-BB78A91E87C9Q37426506-8503AC74-5FF3-4891-BB42-088735F0D126Q37692720-ECD14049-7BD0-429F-908A-2E57C729F5D4Q37693270-F5739477-1048-422F-B24C-1A0B9E753424Q38764017-ECD3C539-8498-4900-AF3C-5E9B86E743A1Q39372999-25DD3A31-F7A9-4B2F-8A76-53552FACCE5DQ39998314-A014F018-FBF6-4510-950E-6E2B212EFFDDQ40572491-09D59A0A-A38A-45B3-ABBC-94B3021673BAQ40572656-C590E27E-3A9F-4CBE-B0A8-69E046C5A248Q40602772-AD0A8ACA-DCC8-4734-90C9-D7FBAB1D45ADQ40820294-9A6A937A-DFB2-4390-87E2-A0DF55DA09AEQ40978833-D4FD440C-F1F7-45E3-A66B-7D8C2739FCE2Q41094611-E8A65B95-7F74-4A4B-BB19-56DB6166B59F
P2860
NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
NS-398, a novel non-steroidal ...... auses minimal stomach lesions.
@en
type
label
NS-398, a novel non-steroidal ...... auses minimal stomach lesions.
@en
prefLabel
NS-398, a novel non-steroidal ...... auses minimal stomach lesions.
@en
P2093
P1433
P1476
NS-398, a novel non-steroidal ...... auses minimal stomach lesions.
@en
P2093
Hamasaka Y
Yoshikawa K
P304
P356
10.1016/0306-3623(93)90018-S
P577
1993-01-01T00:00:00Z